PRIME (PRIority MEdicines) is the European Medicines Agency’s scheme for early, enhanced regulatory support to medicines that target an unmet medical need — the EU’s closest analog to FDA’s Breakthrough Therapy and Fast Track designations, though it runs as a single unified track rather than four separate programs. Launched in March 2016 following adoption by EMA’s Committee for Medicinal Products for Human Use (CHMP), PRIME gives an eligible development program a dedicated rapporteur, an early kick-off meeting with multidisciplinary EMA experts, iterative scientific advice at development milestones, and confirmed eligibility for accelerated assessment once a marketing authorisation application (MAA) is filed. In March 2026, EMA published Progressing EMA’s PRIority Medicines scheme through new pilot features, reporting on a completed two-year pilot of three additional tools — development roadmaps and product trackers, expedited scientific advice, and submission-readiness meetings — that are now rolled into how PRIME operates going forward. This guide covers what PRIME is, who qualifies, what designation confers, the 2026 pilot features, and how the scheme compares to the FDA’s expedited pathways.
What PRIME Is and Why It Exists
PRIME is not a faster review clock in the way FDA’s Priority Review is — it is a development-support scheme that front-loads regulatory engagement into the years before a marketing authorisation application is ever filed. The premise is that medicines addressing serious unmet medical needs often fail, or take longer than necessary to reach patients, because sponsors design pivotal trials without enough early regulatory input on what evidence will actually support approval. PRIME addresses that by assigning a rapporteur (and, from CHMP or the Committee for Advanced Therapies as relevant) early in development, well before the confirmatory-trial design is locked, so that scientific advice can shape the evidence package rather than critique it after the fact.
This makes PRIME closest in intent to FDA’s Breakthrough Therapy designation (intensive early FDA guidance) crossed with elements of Fast Track (more frequent formal interaction), rather than a direct equivalent of either. See CASRAI’s FDA Expedited Programs guide for how the four US pathways relate to each other, and the EMA vs. FDA comparison for how the two agencies’ overall regulatory architectures diverge.
Eligibility Criteria
EMA states explicitly that PRIME eligibility criteria are the same substantive criteria used for accelerated assessment of a marketing authorisation application — applied at a much earlier development stage, where the evidence is necessarily more preliminary and the uncertainty correspondingly higher. To be granted PRIME access, a medicine must generally satisfy both of the following:
- Unmet medical need. The medicine targets a disease or condition for which no satisfactory method of diagnosis, prevention, or treatment exists in the EU, or, where a treatment does exist, the medicine may offer a major therapeutic advantage over what is currently available.
- Meaningful improvement in clinical outcomes. The applicant must present data indicating the medicine has the potential to bring a meaningful improvement to clinical outcomes — in practice, this typically means proof of concept in humans is already available. EMA’s own guidance describes the ideal window to apply as the point when first-in-human data exists and shows a clear signal of benefit; applying earlier than that, with only nonclinical data, is generally premature.
Applicants normally apply during the exploratory clinical development phase. Small and medium-sized enterprises (SMEs) and academic/non-profit sponsors are given more latitude and can apply somewhat earlier, with proof-of-principle rather than full proof-of-concept data, reflecting that these sponsor types often have fewer resources to generate a complete early package before seeking support. Orphan-designated medicines and advanced therapy medicinal products (ATMPs) are common applicant categories, though PRIME eligibility is assessed independently of — and is not contingent on — orphan drug status; see CASRAI’s orphan drug designation guide for how that separate FDA-side pathway is assessed (EMA runs an analogous but distinct orphan medicinal product designation process).
How to Apply
Requests are submitted through EMA’s secure online IRIS platform. CHMP (or CAT for advanced therapies) evaluates each eligibility request and adopts a recommendation, generally within around 40-70 days depending on whether clarification is requested from the applicant mid-review. The applicant is informed of the outcome by letter following CHMP adoption. A rejected request is not necessarily final — sponsors can reapply once additional supportive data becomes available, most commonly once more mature clinical evidence closes the gap the committee identified.
What PRIME Designation Confers
Once granted, PRIME status brings a defined set of benefits, not merely a badge:
- Early rapporteur appointment — typically within one month of PRIME entry, well ahead of the point at which a rapporteur would normally be appointed for a standard MAA.
- A kick-off meeting with a multidisciplinary group of EMA experts to map out the overall development plan and identify the regulatory and methodological questions that matter most.
- Iterative scientific advice at key development milestones, rather than the more transactional, single-point scientific advice available to non-PRIME programs.
- Eligibility confirmation for accelerated assessment at the point of MAA submission, which shortens CHMP’s active review clock from the standard 210 days to 150 days (exclusive of clock-stops).
- As of the 2026 pilot-feature rollout described below, development roadmaps, expedited scientific advice, and a formal submission-readiness meeting roughly a year ahead of MAA filing.
The March 2026 Pilot Features Report
In March 2026, EMA published Progressing EMA’s PRIority Medicines scheme through new pilot features, reporting the results of a two-year pilot of three additional tools layered onto the existing PRIME framework and confirming their integration into standard PRIME operation going forward:
- Development roadmap and product development tracker. A structured roadmap is established for each PRIME development, paired with a tracker that charts progress against it, making it easier for both the sponsor and EMA to stay aligned on timelines and flag emerging issues early rather than discovering them at MAA submission.
- Expedited scientific advice. A faster route to targeted regulatory input for PRIME programs that hit a specific development problem after already receiving comprehensive initial advice — intended for narrow, time-sensitive questions rather than a full advice procedure.
- Submission-readiness meetings. Held approximately one year ahead of the anticipated MAA submission, these meetings review development status, how prior scientific advice has been implemented, and the sponsor’s plans for post-marketing evidence generation, giving both sides a structured checkpoint before the formal filing.
EMA has framed the rollout as part of the agency’s preparation for the revised EU pharmaceutical legislation, which is expected to formally codify PRIME within the new legislative framework rather than leave it solely as an agency-run administrative scheme — a step toward giving PRIME a firmer legal basis than it has had since its 2016 launch.
PRIME by the Numbers
EMA’s published eligibility statistics show PRIME remains a selective pathway, not an easy designation to obtain:
- 2024: EMA received 58 PRIME eligibility requests and CHMP adopted 56 recommendations on those requests; 15 medicines were granted access to the scheme — an approval rate of roughly 27% of adopted recommendations.
- Since the March 2016 launch: EMA has received more than 800 PRIME eligibility requests in total, of which approximately 200 medicines have been granted PRIME designation — a cumulative grant rate in the neighborhood of 25%, broadly consistent with the 2024 figure.
The consistency between the single-year and decade-long grant rates suggests the scheme’s selectivity has been stable over time rather than loosening or tightening sharply as volume has grown — useful context for a sponsor assessing how competitive an eligibility request is likely to be before investing in the application.
PRIME vs. FDA’s Expedited Programs
Sponsors running parallel EU/US development programs are the most common audience asking how PRIME lines up against FDA’s expedited pathways. The short version: PRIME most closely resembles a hybrid of Breakthrough Therapy designation (deep, iterative early engagement) and Fast Track (frequent formal touchpoints), while EMA’s accelerated assessment — the shortened 150-day CHMP review clock that PRIME status feeds into — is the closer functional analog to FDA’s Priority Review. There is no EU designation that maps precisely onto FDA’s Accelerated Approval, which is specifically about accepting a surrogate or intermediate clinical endpoint as a basis for approval; EMA has a separate mechanism, conditional marketing authorisation, for comparable surrogate-endpoint-based early approval, and it is a distinct process from PRIME. For the full pathway-by-pathway breakdown of the four FDA programs, see CASRAI’s FDA Expedited Programs guide; for the broader structural differences between the two agencies (submission format, review body structure, post-approval obligations), see EMA vs. FDA: Regulatory Pathways for Clinical Trials and Drug Approval.
Frequently Asked Questions
Is PRIME the same thing as FDA Breakthrough Therapy designation?
No. They are separately administered by different agencies under different legal frameworks, and their eligibility criteria and specific benefits are not identical, even though both exist to front-load regulatory engagement into early development for medicines addressing serious unmet needs. A sponsor running a global program frequently pursues both, but neither designation is contingent on, or automatically conferred by, holding the other.
Does PRIME guarantee marketing authorisation?
No. PRIME confers enhanced development support and eligibility to request accelerated assessment at the point of MAA submission — it does not guarantee a positive CHMP opinion or eventual European Commission approval. The medicine must still generate the confirmatory efficacy and safety evidence needed to support a benefit-risk determination at filing.
Can a medicine hold both PRIME and orphan designation?
Yes. The two are assessed independently under separate legal frameworks, and many PRIME-designated medicines are also orphan-designated, since rare-disease treatments frequently satisfy PRIME’s unmet-medical-need criterion. Holding one does not require or automatically confer the other.
What happens if a PRIME-designated program is discontinued or fails to reach MAA submission?
PRIME status lapses with the program itself; there is no independent penalty or clawback for a sponsor whose PRIME-supported candidate does not progress to submission, though EMA’s public PRIME statistics track how many designated programs go on to reach a positive CHMP recommendation as a measure of the scheme’s overall effectiveness.
